Studies have shown that therapeutic upregulation of CEBPA leads to inactivation of immunosuppressive myeloid cells and has effective anti-tumor responses in different tumor models and cancer patients (Hashimoto et al., 2021). This evidence concerns the gene CEBPA and neoplasm.